Virbac Shares Dip to €357.50, Testing 50-Day Moving Average
Midday sees Carros-based veterinary lab Virbac down 1.92% at €357.50, while the SBF 120 drops 0.81%. The stock is moving in a downward Parisian market, weighed down by ongoing tensions in the Middle East and Brent crude rising above $103. Over a year, the stock is still up 16.83%.
A Retreat That Brings the Stock to Its 50-Day Moving Average
Today's decline brings Virbac to its 50-day moving average, located at €357.87, with a negligible gap of -0.10%. However, the price has fallen below its 20-day average (€369.90) by -3.35%. The 200-day average remains at €347.56, which is 2.86% below the current price: the medium-term trend remains bullish. The Bollinger Bands place the stock 13% from the lower channel boundary (lower bound at €353.14, upper bound at €386.66), a setup indicating recent selling pressure and positioning the stock in a potential oversold zone. The RSI at 48 remains neutral. The support identified at €347.50 precisely matches the long-term moving average, making it the most relevant short-term monitoring zone. Resistance is at €384.00. With a negative beta of -0.30 and a monthly volatility of 7.25%, the stock historically moves counter to the broader market: today's session, aligned with the SBF 120's decline, is an exception.
Solid Organic Growth in Q1, Next Update Due End of July
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The lab had reported revenue of €384 million in the first quarter of 2026, up 7.7% on a like-for-like and constant currency basis. At actual exchange rates, growth is reduced to 2.2%, highlighting the adverse impact of currency fluctuations on the group's reported performance. More recently, Virbac continued its documentary series dedicated to veterinarians and farmers, focusing on an Iberian pig farm in Extremadura. This communication initiative does not directly affect today's stock price. The financial calendar lists the annual general meeting on June 26, 2026, followed by the Q2 revenue release on July 20. The half-year results are expected on September 17, with an SFAF meeting the following day. Over the past twelve months, the stock has maintained a gain of 16.83% despite a weekly performance of -3.77%. The 50-day moving average, now in contact with the price, remains the technical reference to watch in the coming sessions.
SectorPharmacie et biotechnologies›Pharmacie, vaccins et santé animale
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 1 168 millions d'euros
Quarterly revenue: 1 168 millions d'euros
Guidance from the release
Notre solide performance à fin septembre 2026 nous permet de viser le haut de notre fourchette initiale de croissance du chiffre d'affaires
Risks mentioned
Effets de change défavorables impactant la croissance réelle (croissance réelle +5,9% vs +7,9% à taux constants)
Pression concurrentielle persistante sur les vaccins porcins en Asie de l'Est et pressions tarifaires au segment Animaux d'élevage
Exposition au Moyen-Orient et suivi des tendances inflationnistes (énergie) malgré anticipation d'impacts limités
Opportunities identified
Croissance soutenue des plateformes Supercharge (+11% environ) couvrant petfood, reproduction, dentaire, mobilité, otologie, endocrinologie et ruminants
Intégration fluide de Thyronorm dans la franchise d'endocrinologie avec contribution de +1 point de croissance et +0,5 point d'Ebit ajusté
Redémarrage réussi de la production du contrat majeur de façonnage en Amérique du Nord (juillet 2026) après contrainte réglementaire temporaire
Outlook / guidance
Expected revenue: 1 575 millions d'euros
Management commentary: « Bien que nos perspectives pour l'ensemble de l'année 2026 restent inchangées, notre solide performance à fin septembre (croissance de +7,9%) nous permet de viser la borne haute de notre fourchette de croissance du chiffre d'affaires de 5,5 % à 7,5 % à PCC »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
